Search

Your search keyword '"Stuart, Katherine A"' showing total 157 results
Start Over Author "Stuart, Katherine A" Language english
157 results on '"Stuart, Katherine A"'

1. A randomised controlled trial of Standard Of Care versus RadioAblaTion in Early Stage HepatoCellular Carcinoma (SOCRATES HCC)

Author

Wigg, Alan, Tibballs, Jonathan, Woodman, Richard, Stuart, Katherine, Le, Hien, Roberts, Stuart K., Olynyk, John K., Strasser, Simone I., Wallace, Michael, Martin, Jarad, Haworth, Annette, Hardcastle, Nicholas, Loo, Kee Fong, Tang, Colin, Lee, Yoo Young, Chu, Julie, De Abreu Lourenco, Richard, Koukourou, Adam, De Boo, Diederick, McLean, Kate, Buck, Jackie, Sawhney, Rohit, Nicoll, Amanda, Dev, Anouk, Wood, Marnie, Braund, Alicia, Weltman, Martin, Khor, Richard, Levy, Miriam, Wang, Tim, Potter, Michael, Haridy, James, Raj, Ashok, Duncan, Oliver, Zekry, Amany, Collier, Natalie, O’Beirne, James, Holliday, Catherine, Trada, Yuvnik, Tronidjaja, Jaw, George, Jacob, and Pryor, David

Published
2024
Full Text
View/download PDF

4. Clinically Significant Fibrosis Is Associated With Longitudinal Increases in Fibrosis-4 and Nonalcoholic Fatty Liver Disease Fibrosis Scores

Author

Patel, Preya Janubhai, Cheng, Johnson Chieh-Yu, Banh, Xuan, Gracen, Lucy, Radford-Smith, Daniel, Hossain, Fabrina, Horsfall, Leigh Ula, Hayward, Kelly Lee, Williams, Suzanne, Johnson, Tracey, Brown, Nigel Neil, Saad, Nivene, Stuart, Katherine Anne, Russell, Anthony William, Valery, Patricia Casarolli, Clouston, Andrew Donald, Irvine, Katharine Margaret, Bernard, Anne, and Powell, Elizabeth Ellen

Published
2020
Full Text
View/download PDF

5. The Hidden Epidemic: The Prevalence and Impact of Concurrent Liver Diseases in Patients Undergoing Liver Transplantation in Australia and New Zealand

Author

Howell, Jess, Majumdar, Avik, Fink, Michael, Byrne, Mandy, McCaughan, Geoff, Strasser, Simone I., Crawford, Michael, Hodgkinson, Peter, Stuart, Katherine A., Tallis, Caroline, Chen, John, Wigg, Alan, Jones, Robert, Jaques, Bryon, Jeffrey, Gary, Adams, Leon, Wallace, Michael C., Gane, Ed, Thompson, Alex, and Gow, Paul

Published
2022
Full Text
View/download PDF

7. Efficacy and Safety of Mycophenolate Mofetil in Patients With Autoimmune Hepatitis and Suboptimal Outcomes After Standard Therapy

Author

Roberts, Stuart K., Lim, Ricky, Strasser, Simone, Nicoll, Amanda, Gazzola, Alessia, Mitchell, Joanne, Siow, Way, Khoo, Tiffany, Hamarneh, Zaki, Weltman, Martin, Gow, Paul, Janko, Natasha, Tse, Edmund, Mishra, Gauri, Cheng, En-Hsiang, Levy, Miriam, Cheng, Wendy, Sood, Siddharth, Skoien, Richard, Mitchell, Jonathan, Zekry, Amany, George, Jacob, MacQuillan, Gerry, Wigg, Alan, Stuart, Katherine, Sievert, William, and McCaughan, Geoffrey

Published
2018
Full Text
View/download PDF

8. Prophylactic Acetaminophen or Ibuprofen Result in Equivalent Acute Mountain Sickness Incidence at High Altitude: A Prospective Randomized Trial

Author

Kanaan, Nicholas C., Peterson, Alicia L., Pun, Matiram, Holck, Peter S., Starling, Jennifer, Basyal, Bikash, Freeman, Thomas F., Gehner, Jessica R., Keyes, Linda, Levin, Dana R., O’Leary, Catherine J., Stuart, Katherine E., Thapa, Ghan B., Tiwari, Aditya, Velgersdyk, Jared L., Zafren, Ken, and Basnyat, Buddha

Published
2017
Full Text
View/download PDF

11. Individual Gestalt Is Unreliable for the Evaluation of Quality in Medical Education Blogs: A METRIQ Study

Author

Thoma, Brent, Sebok-Syer, Stefanie S., Krishnan, Keeth, Siemens, Marshall, Trueger, Seth N., Colmers-Gray, Isabelle, Woods, Rob, Petrusa, Emil, Chan, Teresa, Alexander, Charlotte, Alkhalifah, Mohammed, Alqahtani, Saeed, Anderson, Scott, Anderson, Shelaina, Andrews, Colin, Andruko, Jocelyn, Ankel, Felix, Antony, Nikytha, Aryal, Diptesh, Backus, Barbra, Baird, Jennifer, Baker, Andrew, Batty, Sarah, Baylis, Jared, Beaumont, Braeden, Belcher, Chris, Benavides, Brent, Benham, Michael, Pelletier, Elyse Berger, Botta, Julian, Bouchard, Nicholas, Brazil, Victoria, Brumfield, Emily, Bryson, Anthony, Bunchit, Wisarut, Butler, Kat, Buzikievich, Lindy, Calcara, David, Carey, Rob, Carroll, Stephen, Lyons, Casey, Cassidy, Louise, Challen, Kirsty, Chaplin, Tim, Chatham-Zvelebil, Natasha, Chen, Eric, Chen, Lucy, Chhabra, Sushant, Chin, Alvin, Chochi, Eric, Choudhri, Tina, Christensen, Jeremy, Colmers-Gray, Isabelle, Connors, Kimberly, Coppersmith, Veronica, Cosgrove, Abby, Costello, Gregory, Cullison, Kevin, DʼAlessandro, Andrew, de Wit, Kerstin, Decock, Marie, Delbani, Rayan, Denq, William, Deutscher, Julianna, Devine, Brendan, Dorsett, Maia, Duda, Taylor, Dueweke, Justin, Dunphy, Teresa, Dyer, Sean, Eastley, Kathryn T., Edmonds, Marcia, Edwards, Ken, Ehrman, Robert, Elkhalidy, Youness, Fedor, Preston, Ficiur, Brian, Flynn, Caley, Fraser, Bill, Fu, Meagan, Fukakusa, James, Funk, Eric, Gaco, Damjan, Gawlik, Viktor, Ghaffarian, Kenn, Gharahbaghian, Laleh, Griffith, Phil, Griffith, Andrew, Grock, Andrew, Gronowski, Tanner, Grossman, Cathy, Gucwa, Jaroslaw, Gupta, Pawan, Gustafson, Alexandra, Guy, Andrew, Haas, Mary, Haciski, Stanislaw, Hajdinjak, Emina, Hall, Andrew K., Hammock, Regina, Hansel, Jan, Hart, Alexander, Hattin, Larissa, Herb, Brandon, Hilbert, SueLin, Hill, Jesse, Hill, Jeff, Ho, Amy, House, Emily, House, Nina, Huffman, James, Inboriboon, Charlie, Ireland, Alex, Jamal, Mohammed Ali, Jansen, Victor, Jarou, Zach, Jia, Vivian, Johnston, Levi, Kalnow, Drew, Kapur, Puneet, Kelly, Seth, Kelson, Kyle, Kent, William, Khakhkhar, Rishi, Khurana, Jaasmit, Kilp, Ashley, Knapp, Scott, Kohler, Sebastian, Kruhlak, Ivanna, Lalani, Nadim, Lam, Samantha, Lank, Patrick, Laurie, Zander, Lea, Kristina, Leber, Ernest, Lee, Ching-Hsing, Lenes, Haakon, Lenora, Nilantha, Leontowicz, Jesse, Lien, Kelly, Lin, Yingchun, Lin, Michelle, Little, Andrew, Liu, Ivy, Liu, Harry, Liu, Steve, Louka, Stephanie, Lovell, Elise, Lowe, David, Lubberdink, Ashley, Luc, Jessica, Ma, Sheng-Hsiang, MacLeod, Hugh, Mancuso, Nick, Maneshi, Anali, Carrillo, Dra. Maria Rosa, May, Jesse, Mayo, John, McDonnell, Mike, McLellan, Susan, McQuarrie, Carolyn, Nood, Julia, Mead, Therese, Meeuwisse, Cory, Meloy, Patrick, Menzies, Perry, Messman, Anne, Miazga, Stephen, Mills, Logan, Milne, Ken, Mix, Allan, Montag, Steve, Moore, Brendon, Morgenstern, Justin, Mott, Sarah, Mukherj, P., Mulla, Ali, Nandalal, Sheena, Nikel, Taylor, Nugent, Sean, Oakland, Morgan, Oberholzer, Werner, Otugo, Onyeka, Oyedokun, Taofiq Segun, Paddock, Mike, Pardhan, Alim, Patel, Kinjal, Paterson, Quinten, Patocka, Catherine, Patterson, Christine, Pearlman, James, Pelletier-Bui, Alexis, Phan, Marc, Poonja, Zafrina, Powell, Aubrey, Premkumar, Kamini, Prosen, Gregor, Puri, Vishal, Quaife, Tanis, Raffel, Ryan, Raja, Ali, Ramunno, Randi, Rang, Louise, Rannazzisi, Suzanne, Regan, Shauna, Ridderikhof, Milan, Rogers, Vanessa, Roh, Christine, Rosenberg, Keith, Roure, Marina, Rudinsky, Sherri, Rudner, Joshua, Saleh, Adeeb, Sanderson, Will, Scheirer, Owen, Schofield, Paul, Schunk, Paul, Schwarz, Evan, Shahrabadi, Parisa, Shappell, Eric, Sheffield, Julia, Sherbino, Jonathan, Singh, Manpreet, Singson, Hector C., Slessor, Dave, Smith, Sam, Sneath, Paula, Sobehart, Robert, Spearing, Kerry, Stempien, James, Sternard, Britni, Stratton, Tara, Stuart, Katherine, Stuntz, Bob, Susalla, Michael, Sweeney, Colleen, Swisher, Loice, Swoboda, Henry, Syed, Shahbaz, Taira, Taku, Tambe, Nikhil, Tang, Richard, Targonsky, Elisha, Taylor, Rachel, Taylor, Alan, Taylor, Todd, Ting, Paxton, Tiwald, Gerhard, Tran, Kelvin, Tran, Evelyn, Trickovic, Jason, Trinquero, Paul, Trueger, Seth, Tyagi, Aaron, Umana, Manrique, Vallance, Patrick, Van den Berg, Patricia, Vargas, Luis, Verbeek, Rene, Viggers, Sandra, Vlodaver, Zlata, Wagner, Matthew, Walji, Noorin, Walter, Joe, Wan, Miranda, Wang, Rachel, Wanner, Gregory, Warawa, Wyatt, Ward, Mike, Weekes, Jennifer, Weersink, Kristen, Weessies, Cara, Whalen-Browne, Anna, Whiteside, Brian, Willis, Matthew, Wilmer, Jonas, Wong, Nelson, Woodcroft, Mark, Woods, Rob, Yau, Lawrence, Yee, Jessica, Yeh, Calvin, Huang, Simon York Ming, Yurkiw, Katherine, Zaver, Fareen, and Zozula, Alexander

Published
2017
Full Text
View/download PDF

12. Low Prevalence of Use of Allied Health and Community Services for Patients with Cirrhosis in Australia: A Need for Greater Engagement.

Author

Powell, Elizabeth E, Stuart, Katherine A, Finnigan, Simon, Hinson, Jan, Bernardes, Christina M, Hartel, Gunter, and Valery, Patricia C

Subjects
*GENERAL practitioners, *PSYCHIATRIC social work, *MEDICAL care, *COMMUNITY health services, *CIRRHOSIS of the liver
Abstract

Background: Psychosocial, lifestyle and practical needs are not routinely attended to during outpatient hepatology management, and little is known about the type and effectiveness of support services accessed by patients with cirrhosis. We quantified the type and use of community and allied health services in patients with cirrhosis. Methods: The study included 562 Australian adults with a diagnosis of cirrhosis. Health service use was assessed via questionnaire and via linkage to the Australian Medicare Benefits Schedule. Patient needs were assessed using the Supportive Needs Assessment tool for Cirrhosis (SNAC). Results: Although most patients (85.9%) used at least one community/allied health service for support with their liver disease, many reported requiring additional help with psychosocial (67.4%), lifestyle (34.3%) or practical needs (21.9%) that were not met by available services, or patients did not access services. A multidisciplinary care plan or case conference (in the 12 months prior to recruitment) was accessed by 48% of patients, 56.2% reported the use of a general practitioner for support with cirrhosis, and a dietician was the allied health clinician most accessed by patients (45.9%). Despite the high prevalence of psychosocial needs, there was relatively limited use of mental health and social work services (14.1% of patients reported the use of a psychologist), confirmed by a low prevalence of use of mental health services (17.7%) in the linked data. Conclusion: Patients with cirrhosis who have unmet complex physical and psychosocial needs require better strategies to increase their engagement with allied health and community services. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

13. Refining stereotactic body radiation therapy as a bridge to transplantation for hepatocellular carcinoma: An institutional experience.

Author

Chen, Beini, Butler, Nick, O'Rourke, Thomas, Hodgkinson, Peter, Stuart, Katherine, Shih, Edwin, Leggett, David, Pryor, David, Liu, Howard, and Lee, Dominique

Subjects
STEREOTACTIC radiotherapy, HEPATOCELLULAR carcinoma, PREOPERATIVE risk factors, BRIDGES, PATIENT selection, HEART assist devices
Abstract

Background: Stereotactic body radiotherapy (SBRT) has been established as a safe and effective treatment for hepatocellular carcinoma (HCC). Currently, there are no consensus guidelines to advise optimal patient selection and radiotherapy planning parameters to minimise the risk of surgical and medical complications after liver transplant (LT) in patients who have had prior SBRT for HCC, whilst optimising treatment benefit. Methods: We performed a retrospective analysis of all adult patients who received liver SBRT as a bridge to LT at a tertiary institution between 2017 and 2019. Results: Nine patients received SBRT as bridging therapy to LT. HCC location varied from peripheral to central/hilar regions and HCC diameter was 13–54 mm. Median time between SBRT and LT was 141 days (range 27–461 days). Median operating time was 360 min (range 270–480 min). Four patients (44%) had visible SBRT reaction or fibrosis at the time of LT. SBRT reaction resulted in clinical impact in one patient (11%) only, where vascular clamping of the IVC was required for 10 min. Conclusion: SBRT is a safe and effective treatment for HCC enabling patients to remain within LT criteria, even for lesions not amenable to other more conventional bridging therapies. We describe a preliminary decision pathway to guide the optimal use of SBRT as a bridge to LT developed in our institution. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

14. Higher levels of supportive care needs are linked to higher health service use and cost, poor quality of life, and high distress in patients with cirrhosis in Queensland, Australia.

Author

Valery, Patricia C., Stuart, Katherine A., Bernardes, Christina M., Hartel, Gunter, Martin, Cathy, Gordon, Louisa, and Powell, Elizabeth E.

Subjects
PSYCHOLOGICAL distress, MEDICAL care, QUALITY of life, LIVER disease etiology, MEDICAL record linkage
Abstract

Background: Australians with cirrhosis have significant practical and psychosocial needs. This longitudinal study examined the association between supportive care needs and health service use and costs, and patient outcomes from June 2017 to December 2018. Methods: The Supportive Needs Assessment tool for Cirrhosis (SNAC), quality of life (Chronic Liver Disease Questionnaire and Short Form 36), and distress (distress thermometer) were self-reported through an interview at recruitment (n=433). Clinical data were obtained from medical records and through linkage, and health service use and costs through linkage. Patients were grouped as by needs status. Rates of hospital admissions (per person days at risk) and costs were assessed by needs status [incidence rate ratios (IRR), Poisson regression]. Multivariable linear regression was used to assess the differences in SNAC scores by quality of life and distress. Multivariable models included Child-Pugh class, age, sex, recruitment hospital, living arrangements, place of residence, comorbidity burden, and primary liver disease etiology. Results: In adjusted analyses, compared with patients with low/no needs, patients with unmet needs had more cirrhosis-related admissions (adjusted IRR=2.11, 95% CI=1.48-3.13; p<0.001), admissions through the emergency department (IRR=2.99, 95% CI=1.80-4.97, p<0.001), and emergency presentations (IRR=3.57, 95% CI=1.41-9.02; p<0.001). Total hospitalization costs for cirrhosis admissions were higher for those with unmet needs ($431,242 per person days at risk) compared with those with met needs ($87,363 per person days at risk, adjusted cost ratio=3.52, 95%CI=3.49-3.54; p<0.001). In multivariable analysis, increasing overall mean SNAC scores (higher needs) were correlated with poorer quality of life and higher level of distress (p<0.001 for all comparisons). Conclusions: Patients with cirrhosis and high unmet psychosocial needs and practical and physical needs have poor quality of life, high distress, and very high service use and costs, highlighting the importance of urgently addressing unmet needs. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

15. Global multi-stakeholder endorsement of the MAFLD definition

Author

Abate, Maria Lorena, Abbas, Bahaa, Abbassy, Ahmed Amr, Abd El Ghany, Waleed, Abd Elkhalek, Amira, Abd ElMajeed, Emad, Abdalgaber, Mohammad, AbdAllah, Mohamed, Abdallah, Marwa, Abdallah, Nourhan, Abdelaleem, Shereen, Abdelghani, Yasser, Abdelghany, Wael, Abdelhalim, Safaa Mohamed, Abdelhamid, Wafaa, Abdelhamid, Nehal, Abdelkader, Nadia A., Abdelkreem, Elsayed, Abdelmohsen, Aly Mohamed, Abdelrahman, Awny Ali, Abd-elsalam, Sherief M, Abdeltawab, Doaa, Abduh, Abdulbaset, Abdulhakam, Nada, Abdulla, Maheeba, Abedpoor, Navid, Abenavoli, Ludovico, Åberg, Fredrik, Ablack, Omala, Abo elftouh, Mostafa, Abo-Amer, Yousry Esam-Eldin, Aboubkr, Ashraf, Aboud, Alaa, Abouelnaga, Amr M., Aboufarrag, Galal A., Aboutaleb, Ashraf, Abundis, Leticia, Adalı, Gupse, Adames, Enrique, Adams, Leon, Adda, Danjuma, Adel, Noor, Adel, Nada, Adel Sayed, Muhammad, Afaa, Taiba Jibril, Afredj, Nawal, Aghayeva, Gulnara, Aghemo, Alessio, Aguilar-Salinas, Carlos A., Ahlenstiel, Golo, Ahmady, Walid, Ahmed, Wafaa, Ahmed, Amira, Ahmed, Samah Nasser, Ahmed, Heba Mostafa, Ahmed, Rasha, Aigner, Elmar, Akarsu, Mesut, Akroush, Maisam, Akyuz, Umit, Al Mahtab, Mamun, Al Qadiri, Tahani, Al Rawahi, Yusriya, AL rubaee, Razzaq, Al Saffar, Muna, Alam, Shahinul, Al-Ani, Zaid, Albillos, Agustín, Alboraie, Mohamed, Al-Busafi, Said, Al-Emam, Mohamed, Alharthi, Jawaher, Ali, Kareem, Ali, Basma Abdelmoez, Ali, Mohammad, Ali, Raja Affendi Raja, Alisi, Anna, AL-Khafaji, Ali Raad, Alkhatry, Maryam, Aller, Rocio, Almansoury, Yahya, Al-Naamani, Khalid, Alnakeeb, Alaa, Alonso, Anna, Alqahtani, Saleh A., Alrabadi, Leina, Alswat, Khalid, Altaher, Mahir, Altamimi, Turki, Altamirano, Jose, Alvares-da-Silva, Mario R., Aly, Elsragy Adel M., Alzahaby, Amgad, Alzamzamy, Ahmed, Amano, Keisuke, Amer, Maysa A., Amin, Mona A., Amin, Sayed A., Amir, Ashraf A., Ampuero, Javier, Anas, Noha, Andreone, Pietro, Andriamandimby, Soa Fy, Anees, Mahmoud, Angela, Peltec, Antonios, Manal, Arafat, Wael, Araya, Jose Moreno, Armendariz-Borunda, Juan, Armstrong, Matthew J., Ashktorab, Hassan, Aspichueta, Patricia, Assal, Fathia, Atef, Mira, Attia, Dina, Atwa, Hoda, Awad, Reham, Awad, Mohyeldeen Abd Elaziz, Awny, Sally, Awolowo, Obafemi, Awuku, Yaw Asante, Ayada, Ibrahim, Aye, Than Than, Ayman, Sherif, Ayman, Hedy, Ayoub, Hesham, Azmy, Hosny M., Babaran, Romiro P., Badreldin, Omneya, Badry, Ahmed, Bahçecioğlu, İbrahim Halil, Bahour, Amira, Bai, Jiajia, Balaban, Yasemin, Balasubramanyam, Muthuswamy, Bamakhrama, Khaled, Banales, Jesus M, Bangaru, Babu, Bao, Jianfeng, Barahona, Jorge Suazo, Barakat, Salma, Barbalho, Sandra Maria, Barbra, Bikwa, Barranco, Beatriz, Barrera, Francisco, Baumann, Ulrich, Bazeed, Shamardan, Bech, Eva, Benayad, Aourarh, Benesic, Andreas, Bernstein, David, Bessone, Fernando, Birney, Susie, Bisseye, Cyrille, Blake, Martin, Bobat, Bilal, Bonfrate, Leonilde, Bordin, Dmitry S, Bosques-Padilla, Francisco, Boursier, Jerome, Boushab, Boushab Mohamed, Bowen, David, Bravo, Patricia Medina, Brennan, Paul N, Bright, Bisi, Broekaert, Ilse, Buque, Xabier, Burgos-Santamaría, Diego, Burman, Julio, Busetto, Luca, Byrne, Chris D., Cabral-Prodigalidad, Patricia Anne I., Cabrera-Alvarez, Guillermo, Cai, Wei, Cainelli, Francesca, Caliskan, Ali Riza, Canbay, Ali, Cano-Contreras, Ana, Cao, Hai-Xia, Cao, Zhujun, Carrion, Andres, Carubbi, Francesca, Casanovas, Teresa, Castellanos Fernández, Marlen Ivón, Chai, Jin, Chan, Siew Pheng, Charatcharoenwitthaya, Phunchai, Chavez-Tapia, Norberto, Chayama, Kazuaki, Chen, Jinjun, Chen, Lin, Chen, Zhong-Wei, Chen, Huiting, Chen, Sui-Dan, Chen, Qiang, Chen, Yaxi, Chen, Gang, Chen, En-Quang, Chen, Fei, Chen, Pei-Jer, Cheng, Robert, Cheng, Wendy, Chieh, Jack Tan Wei, Chokr, Imad, Cholongitas, Evangelos, Choudhury, Ashok, Chowdhury, Abhijit, Chukwudike, Evaristus Sunday, Ciardullo, Stefano, Clayton, Michelle, Clement, Karine, Cloa, Marie Michelle, Coccia, Cecilia, Collazos, Cristina, Colombo, Massimo, Cosar, Arif Mansur, Cotrim, Helma Pinchemel, Couillerot, Joris, Coulibaly, Alioune, Crespo, Gonzalo, Crespo, Javier, Cruells, Maria, Cua, Ian Homer Y., Dabbous, Hesham K., Dalekos, George N, D'Alia, Patricia, Dan, Li, Dao, Viet Hang, Darwish, Mostafa, Datz, Christian, Davalos-Moscol, Milagros B, Dawoud, Heba, de Careaga, Blanca Olaechea, de Knegt, Robert, de Ledinghen, Victor, de Silva, Janaka, Debzi, Nabil, Decraecker, Marie, Del Pozo, Elvira, Delgado, Teresa C, Delgado-Blanco, Manuel, Dembiński, Łukasz, Depina, Adilson, Derbala, Moutaz, Desalegn, Hailemichael, Desbois-Mouthon, Christèle, Desoky, Mahmoud, Dev, Anouk, Di Ciaula, Agostino, Diago, Moisés, Diallo, Ibrahima, Díaz, Luis Antonio, Dirchwolf, Melisa, Dongiovanni, Paola, Dorofeyev, Andrriy, Dou, Xiaoguang, Douglas, Mark W., Doulberis, Michael, Dovia, Cecil K., Doyle, Adam, Dragojević, Ivana, Drenth, Joost PH, Duan, Xuefei, Dulskas, Audrius, Dumitrascu, Dan L, Duncan, Oliver, Dusabejambo, Vincent, Dwawhi, Rev. Shem N.A., Eiketsu, Sho, El Amrousy, Doaa, El Deeb, Ahmed, El Deriny, Ghada, El Din, Hesham Salah, El Kamshishy, Salwa, El Kassas, Mohamed, El Raziky, Maissa, Elagamy, Osama A, Elakel, Wafaa, Elalfy, Dina, Elaraby, Hanaa, ElAwady, Heba, Elbadawy, Reda, Eldash, Hanaa Hassan, Eldefrawy, Manal S., Elecharri, Carol Lezama, Elfaramawy, Amel, Elfatih, Mohammed, Elfiky, Mahmoud, Elgamsy, Mohamed, Elgendy, Mohamed, El-Guindi, Mohamed A., Elhussieny, Nagi, Eliwa, Ahmed Maher, Elkabbany, Zeineb, El-Khayat, Hesham, El-Koofy, Nehal M., Elmetwalli, Alaa, Elrabat, Amr, El-Raey, Fathiya, Elrashdy, Fatma, Elsahhar, Medhat, Elsaid, Esraa M., Elsayed, Shimaa, Elsayed, Hany, Elsayed, Aly, Elsayed, Amr M., Elsayed, Hamdy, El-Serafy, Magdy, Elsharkawy, Ahmed M., Elsheemy, Reem Yehia, Elshemy, Eman Elsayed, Elsherbini, Sara, Eltoukhy, Naglaa, Elwakil, Reda, Emad, Ola, Emad, Shaimaa, Embabi, Mohamed, Ergenç, Ilkay, Ermolova, Tatiana, Esmat, Gamal, Esmat, Doaa M., Estupiñan, Enrique Carrera, Ettair, Said, Eugen, Tcaciuc, Ezz-Eldin, Mohammed, Falcón, Lidia Patricia Valdivieso, Fan, Yu-Chen, Fandari, Samah, Farag, Mahmoud, Farahat, Taghreed Mohamed, Fares, Eman M., Fares, Michael, Fassio, Eduardo, Fathy, Hayam, Fathy, Dina, Fathy, Wael, Fayed, Soheir, Feng, Dan, Feng, Gong, Fernández-Bermejo, Miguel, Ferreira, Cristina Targa, Ferrer, Javier Díaz, Forbes, Alastair, Fouad, Rabab, Fouad, Hanan M., Frisch, Tove, Fujii, Hideki, Fukunaga, Shuhei, Fukunishi, Shinya, Fulya, Hacer, Furuhashi, Masato, Gaber, Yasmine, Galang, Augusto Jose G., Gallardo, Jacqueline Cordova, Galloso, Rocío, Gamal, Mahmoud, Gamal, Reham, Gamal, Hadeel, Gan, Jian, Ganbold, Anar, Gao, Xin, Garas, George, Garba, Tony, García-Cortes, Miren, García-Monzón, Carmelo, García-Samaniego, Javier, Gastaldelli, Amalia, Gatica, Manuel, Gatley, Elizabeth, Gegeshidze, Tamar, Geng, Bin, Ghazinyan, Hasmik, Ghoneem, Salma, Giacomelli, Luca, Giannelli, Gianluigi, Giannini, Edoardo G., Giefer, Matthew, Ginès, Pere, Girala, Marcos, Giraudi, Pablo J, Goh, George Boon-Bee, Gomaa, Ahmed Ali, Gong, Benbingdi, Gonzales, Dina Hilda C., Gonzalez, Humberto C., Gonzalez-Huezo, Maria Saraí, Graupera, Isabel, Grgurevic, Ivica, Grønbæk, Henning, Gu, Xuelian, Guan, Lin, Gueye, Ibrahima, Guingané, Alice Nanelin, Gul, Ozen Oz, Gul, Cuma Bulent, Guo, Qing, Gupta, Pramendra Prasad, Gurakar, Ahmet, Gutierrez, Juan Carlos Restrepo, Habib, Ghada, Hafez, Azaa, Hagman, Emilia, Halawa, Eman, Hamdy, Osama, Hamed, Abd Elkhalek, Hamed, Dina H., Hamid, Saeed, Hamoudi, Waseem, Han, Yu, Haridy, James, Haridy, Hanan, Harris, David C H Harris, Hart, Michael, Hasan, Fuad, Hashim, Almoutaz, Hassan, Israa, Hassan, Ayman, Hassan, Essam Ali, Hassan, Adel Ahmed, Hassan, Magda Shehata, Hassanin, Fetouh, Hassnine, Alshymaa, Haukeland, John Willy, Hawal, Amr Ismael M., He, Jinfan, He, Qiong, He, Yong, He, Fang-Ping, Hegazy, Mona, Hegazy, Adham, Henegil, Osama, Hernández, Nelia, Hernández-Guerra, Manuel, Higuera-de-la-Tijera, Fatima, Hindy, Ibrahim, Hirota, Keisuke, Ho, Lee Chi, Hodge, Alexander, Hosny, Mohamed, Hou, Xin, Huang, Jiao-Feng, Huang, Yan, Huang, Zhifeng, Huang, Yuan, Huang, Ang, Huang, Xiao-Ping, Hui-ping, Sheng, Hunyady, Bela, Hussein, Mennatallah A., Hussein, Osama, Hussien, Shahinaz Mahmoud, Ibáñez-Samaniego, Luis, Ibdah, Jamal, Ibrahim, Luqman, Ibrahim, Miada, Ibrahim, Ibrahim, Icaza-Chávez, Maria E., Idelbi, Sahar, Idilman, Ramazan Idilman, Ikeda, Mayumi, Indolfi, Giuseppe, Invernizzi, Federica, Irshad, Iram, Isa, Hasan Mohamed Ali, Iskandar, Natacha Jreige, Ismaiel, Abdulrahman, Ismail, Mariam, Ismail, Zulkifli, Ismail, Faisal, Iwamoto, Hideki, Jack, Kathryn, Jacob, Rachael, Jafarov, Fuad, Jafri, Wasim, Jahshan, Helen, Jalal, Prasun K, Jancoriene, Ligita, Janicko, Martin, Jayasena, Hiruni, Jefferies, Meryem, Jha, Vivekanand, Ji, Fanpu, Ji, Yaqiu, Jia, Jidong, Jiang, Changtao, Jiang, Ni, Jiang, Zong-zhe, Jin, Xing, Jin, Yi, Jing, Xu, Jingyu, Qian, Jinjolava, Maia, Jong, FX Himawan Haryanto, Jucov, Alina, Julius, Ibecheole, Kaddah, Mona, Kamada, Yoshihiro, kamal, Abobakr, Kamal, Enas Mohamed, Kamel, Ashraf Sayed, Kao, Jia-Horng, Karin, Maja, Karlas, Thomas, Kashwaa, Mohammad, Katsidzira, Leolin, Kaya, Eda, Kayasseh, M.Azzam, Keenan, Bernadette, Keklikkiran, Caglayan, Keml, William, Khalaf, Deia K., Khalefa, Rofida, Khamis, Sherin, Khater, Doaa, khattab, Hamed, Khavkin, Anatoly, Khlynova, Olga, Khmis, Nabil, Kobyliak, Nazarii, Koffas, Apostolos, Koike, Kazuhiko, Kok, Kenneth Y.Y., Koller, Tomas, Komas, Narcisse Patrice, Korochanskaya, Nataliya V., Koulla, Yannoula, Koya, Shunji, Kraft, Colleen, Kraja, Bledar, Krawczyk, Marcin, Kuchay, Mohammad Shafi, Kulkarni, Anand V, Kumar, Ashish, Kumar, Manoj, Lakoh, Sulaiman, Lam, Philip, Lan, Ling, Lange, Naomi F., Lankarani, Kamran Bagheri, Lanthier, Nicolas, Lapshyna, Kateryna, Lashen, Sameh A., Laure, Konang Nguieguia Justine, Lazebnik, Leonid, Lebrec, Didier, Lee, Samuel S., Lee, Way Seah, Lee, Yeong Yeh, Leeming, Diana Julie, Leite, Nathalie Carvalho, Leon, Roberto, Lesmana, Cosmas Rinaldi Adithya, Li, Junfeng, Li, Qiong, Li, Jun, Li, Yang-Yang, Li, Yufang, Li, Lei, Li, Min, li, Yiling, Liang, Huiqing, Lijuan, Tang, Lim, Seng Gee, Lim, Lee-Ling, Lin, Shumei, Lin, Han-Chieh, Lin, Rita, Lithy, Rania, Liu, Yaru, Liu, Yuanyuan, Liu, Xin, Liu, Wen-Yue, Liu, Shourong, Liu, Ken, Liu, Tian, Lonardo, Amedeo, López, Mariana Bravo, López-Benages, Eva, Lopez-Jaramillo, Patricio, Lu, Huimin, Lu, Lun Gen, Lu, Yan, Lubel, John, Lui, Rashid, Lupasco, Iulianna, Luzina, Elena, Lv, Xiao-Hui, Lynch, Kate, Ma, Hong-Lei, Machado, Mariana Verdelho, Maduka, Nonso, Madzharova, Katerina, Magdaong, Russellini, Mahadeva, Sanjiv, Mahfouz, Amel, Mahmood, Nik Ritza Kosai Nik, Mahmoud, Eman, Mahrous, Mohamed, Maiwall, Rakhi, Majeed, Ammar, Majumdar, Avik, Mak, Loey, Maklouf, Madiha M, Malekzadeh, Reza, Mandato, Claudia, Mangia, Alessandra, Mann, Jake, Mansour, Hala Hussien, Mansouri, Abdellah, Mantovani, Alessandro, Mao, Jun qian, Maramag, Flor, Marchesini, Giulio, Marcus, Claude, Marinho, Rui António Rocha Tato, Martinez-Chantar, Maria L, Martins, Antonieta A. Soares, Marwan, Rana, Mason, Karen Frances, Masoud, Ghadeer, Massoud, Mohamed Naguib, Matamoros, Maria Amalia, Mateos, Rosa Martín, Mawed, Asmaa, Mbanya, Jean Claude, Mbendi, Charles, McColaugh, Lone, McLeod, Duncan, Medina, Juan Francisco Rivera, Megahed, Ahmed, Mehrez, Mai, Memon, Iqbal, Merat, Shahin, Mercado, Randy, Mesbah, Ahmed, Meskini, Taoufik, Metwally, Mayada, Metwaly, Rasha, Miao, Lei, Micah, Eileen, Miele, Luca, Milivojevic, Vladimir, Milovanovic, Tamara, Mina, Yvonne L., Mishkovik, Milan, Mishriki, Amal, Mitchell, Tim, Mohamed, Alshaimaa, Mohamed, Mona, Mohamed, Sofain, Mohammed, Shady, Mohammed, Ahmed, Mohan, Viswanathan, Mohie, Sara, Mokhtar, Aalaa, Moniem, Reham, Montilla, Mabel Segura, Morales, Jose Antonio Orozco, Morata, María María Sánchez, Moreno-Planas, Jose Maria, Morise, Silvia, Mosaad, Sherif, Moselhy, Mohamed, Mostafa, Alaa Mohamed, Mostafa, Ebraheem, Mouane, Nezha, Mousa, Nasser, Moustafa, Hamdy Mahfouz, Msherif, Abeer, Muller, Kate, Munoz, Christopher, Muñoz-Urribarri, Ana Beatriz, Murillo, Omar Alfaro, Mustapha, Feisul Idzwan, Muzurović, Emir, Nabil, Yehia, Nafady, Shaymaa, Nagamatsu, Ayu, Nakajima, Atsushi, Nakano, Dan, Nan, Yuemin, Nascimbeni, Fabio, Naseef, Mirella S., Nashat, Nagwa, Natalia, Taran, Negro, Francesco, Nersesov, Alexander V., Neuman, Manuela, Ng'wanasayi, Masolwa, Ni, Yan, Nicoll, Amanda, Niizeki, Takashi, Nikolova, Dafina, Ningning, Wang, Niriella, Madunil, Nogoibaeva, K.A, Nordien, Rozeena, O Sullivan, Catherine, O'Beirne, James, Obekpa, Solomon, Ocama, Ponsiano, Ochwoto, Missiani, Ogolodom, Michael Promise, Ojo, Olusegun, Okrostsvaridze, Nana, Oliveira, Claudia P., Omaña, Raul Contreras, Omar, Omneya M., Omar, Hanaa, Omar, Mabroka, Omran, Salma, Omran, Reham, Osman, Marian Muse, Owise, Nevin, Owusu-Ansah, Theobald, Padilla- Machaca, P. Martín, Palle, Sirish, Pan, Ziyan, Pan, Xiao-Yan, Pan, Qiuwei, Papaefthymiou, Apostolis, Paquissi, Feliciano Chanana, Par, Gabriella, Parkash, Arit, Payawal, Diana, Peltekian, Kevork M., Peng, Xuebin, Peng, Liang, Peng, Ying, Pengoria, Rahul, Perez, Martina, Pérez, José Luis, Pérez, Norma Marlene, Persico, Marcello, Pessoa, Mário Guimarães, Petta, Salvatore, Philip, Mathew, Plaz Torres, Maria Corina, Polavarapu, Naveen, Poniachik, Jaime, Portincasa, Piero, Pu, Chunwen, Pürnak, Tuğrul, Purwanto, Edhie, Qi, Xiaolong, Qi, Xingshun, Qian, Zibing, Qiang, Zhao, Qiao, Zengpei, Qiao, Liang, Queiroz, Alberto, Rabiee, Atoosa, Radwan, Manal, Rahetilahy, Alain Marcel, Ramadan, Yasmin, Ramadan, Dina, Ramli, Anis Safura, Ramm, Grant A., Ran, Ao, Rankovic, Ivan, RAO, Huiying, Raouf, Sara, Ray, Sayantan, Reau, Nancy, Refaat, Ahmed, Reiberger, Thomas, Remes-Troche, Jose M, Reyes, Eira Cerda, Richardson, Ben, Ridruejo, Ezequiel, Riestra Jimenez, Sergio, Rizk, Ibrahim, Roberts, Stuart, Roblero, Juan Pablo, Robles, Jorge Alberto Prado, Rockey, Don, Rodríguez, Manuel, Rodríguez Hernández, Heriberto, Román, Eva, Romeiro, Fernando Gomes, Romeo, Stefano, Rosales-Zabal, Jose Miguel, Roshdi, Georgina R., Rosso, Natalia, Ruf, Andres, Ruiz, Patricia Cordero, Runes, Nelia R., Ruzzenente, Andrea, Ryan, Marno, Saad, Ahmed, Sabbagh, Eman BE, Sabbah, Meriam, Saber, Shimaa, Sabrey, Reham, Sabry, Ramy, Saeed, Maysaa Abdallah, Said, Dina, Said, Ebada M, Sakr, Mohammad Amin, Salah, Yara, Salama, Rabab Maamoun, Salama, Asmaa, Saleh, Hussein, Saleh, Ahmed, Salem, Ahmed, Salem, Ahmed Thabet, Salifou, Alkassoum, Salih, Aso Faeq, Salman, Abdallah, Samouda, Hanen, Sanai, Faisal, Sánchez-Ávila, Juan Francisco, Sanker, Lakshumanan, Sano, Tomoya, Sanz, Miquel, Saparbu, Tobokalova, Sawhney, Rohit, Sayed, Fatma, Sayed, Sayed A., Sayed, Ashraf Othman, Sayed, Manar, Sebastiani, Giada, Secadas, Laura, Sediqi, Khawaja Qamaruddin, Seif, Sameh, Semida, Nady, Şenateş, Ebubekir, Serban, Elena Daniela, Serfaty, Lawrence, Seto, Wai-Kay, Sghaier, Ikram, Sha, Min, Shabaan, Hamada M., Shalaby, Lobna, Shaltout, Inass, Sharara, Ala I., Sharma, Vishal, Shawa, Isaac Thom, Shawkat, Ahmed, Shawky, Nehal, Shehata, Osama, Sheils, Sinead, Shewaye, Abate Bane, Shi, Guojun, Shi, Junping, Shimose, Shigeo, Shirono, Tomotake, Shou, Lan, Shrestha, Ananta, Shui, Guanghou, Sievert, William, Sigurdardottir, Solveig, Sira, Mostafa Mohamed, Siradj, Riyadh, Sison, Cecilia, Smyth, Linda, Soliman, Reham, Sollano, Jose D, Sombie, Roger, Sonderup, Mark, Sood, Siddharth, Soriano, German, Stedman, Catherine A M, Stefanyuk, Oksana, Štimac, Davor, Strasser, Simone, Strnad, Pavel, Stuart, Katherine, Su, Wen, Su, Minghua, Sumida, Yoshio, Sumie, Shuji, Sun, Dan-Qin, Sun, Jing, Suzuki, Hiroyuki, Svegliati-Baroni, Gianluca, Swar, Mohamed Osman, TAHARBOUCHT, S., Taher, Zenab, Takamura, Saori, Tan, Lin, Tan, Soek-Siam, Tanwandee, Tawesak, Tarek, Sara, Tatiana, Ghelimici, Tavaglione, Federica, Tecson, Gina Y., Tee, Hoi-Poh, Teschke, Rolf, Tharwat, Mostafa, Thong, Vo Duy, Thursz, Mark, Tine, Tulari, Tiribelli, Claudio, Tolmane, Ieva, Tong, Jing, Tongo, Marco, Torkie, Mamdouh, Torre, Aldo, Torres, Esther A, Trajkovska, Meri, Treeprasertsuk, Sombat, Tsutsumi, Tsubasa, Tu, Thomas, Tur, Josep A., Turan, Dilara, Turcan, Svetlana, Turkina, Svetlana, Tutar, Engin, Tzeuton, Christian, Ugiagbe, Rose, Uygun, Ahmet, Vacca, Michele, Vajro, Pietro, Van der Poorten, David, Van Kleef, Laurens A., Vashakidze, Eliza, Velazquez, Carlos Moctezuma, Velazquez, Mirtha Infante, Vento, Sandro, Verhoeven, Veronique, Vespasiani-Gentilucci, Umberto, Vethakkan, Shireene Ratna, Vilaseca, Josep, Vítek, Libor, Volkanovska, Ance, Wallace, Michael, Wan, Wang, Wang, Yan, Wang, Ying, Wang, Xiaolin, Wang, Xuemei, Wang, Chengyan, Wang, Chunjiong, Wang, Mingjie, Wangchuk, Pelden, Weltman, Martin, White, MaryFrances, Wiegand, Johannes, Wifi, Mohamed-Naguib, Wigg, Alan, Wilhelmi, Markus, William, Remon, Wittenburg, Henning, Wu, Shengjie, Wubeneh, Abdu Mohammed, Xia, Hongping, Xiao, Jian, Xiao, Xiao, Xiaofeng, Wang, Xiong, Wanyuan, Xu, Liang, Xu, Jie, Xu, Weiguo, Xu, Jing-Hang, Xu, Keshu, Xu, Yumin, Xu, Shi-Hao, Xu, Meng, Xu, Aimin, Xu, Chengfu, Yan, Hongmei, Yang, Jingyi, Yang, Rui-Xu, Yang, Yating, Yang, Qinhe, Yang, Naibin, Yao, Jia, Yara, Justine, Yaraş, Serkan, Yılmaz, Nimet, Younes, Ramy, younes, Huda, Young, Sona, Youssef, Farah, Yu, Yanyan, Yu, Ming-Lung, Yuan, Jing, Yue, Zhang, Yuen, Man-Fung, Yun, Wang, Yurukova, Nonka, Zakaria, Serag, Zaky, Samy, Zaldastanishvili, Maia, Zapata, Rodrigo, Zare, Nazanin, Zerem, Enver, Zeriban, Nema, Zeshuai, Xu, Zhang, Huijie, Zhang, Xuemei, Zhang, Yupei, Zhang, Wen-Hua, Zhang, Xuchen, Zhang, Yon-ping, Zhang, Yuexin, Zhang, Zhan-qing, Zhao, Jingmin, Zhao, Rong-Rong, Zhao, Hongwei, Zheng, Chao, Zheng, Yijie, Zheng, Ruidan, Zheng, Tian-Lei, Zheng, Kenneth, Zhou, Xi Qiao, Zhou, Yongjian, Zhou, Yu-Jie, Zhou, Hong, Zhou, Ling, Zhou, Yongning, Zhu, Long dong, Zhu, Yong Fen, Zhu, Yueyong, Zhu, Pei-Wu, Ziada, Ebtesam, Ziring, David, Ziyi, Li, Zou, Shanshan, Zou, Zhengsheng, Zou, Huaibin, Zuart Ruiz, Roberto, Méndez-Sánchez, Nahum, Bugianesi, Elisabetta, Gish, Robert G, Lammert, Frank, Tilg, Herbert, Nguyen, Mindie H, Sarin, Shiv K, Fabrellas, Núria, Zelber-Sagi, Shira, Fan, Jian-Gao, Shiha, Gamal, Targher, Giovanni, Zheng, Ming-Hua, Chan, Wah-Kheong, Vinker, Shlomo, Kawaguchi, Takumi, Castera, Laurent, Yilmaz, Yusuf, Korenjak, Marko, Spearman, C Wendy, Ungan, Mehmet, Palmer, Melissa, El-Shabrawi, Mortada, Gruss, Hans-Juergen, Dufour, Jean-François, Dhawan, Anil, Wedemeyer, Heiner, George, Jacob, Valenti, Luca, Fouad, Yasser, Romero‐Gomez, Manuel, and Eslam, Mohammed

Published
2022
Full Text
View/download PDF

16. Methods of Manufacturing Bioactive Gels from Extracellular Matrix Material

Author

Kentner, Kimberly, Stuart, Katherine A, and Janis, Abram D

Subjects
Life Sciences (General)
Abstract

The present invention is directed to methods of manufacturing bioactive gels from ECM material, i.e., gels which retain bioactivity, and can serve as scaffolds for preclinical and clinical tissue engineering and regenerative medicine approaches to tissue reconstruction. The manufacturing methods take advantage of a new recognition that bioactive gels from ECM material can be created by digesting particularized ECM material in an alkaline environment and neutralizing to provide bioactive gels.

Published
2017

17. Development and Evaluation of the Supportive Needs Assessment Tool for Cirrhosis (SNAC)

Author

Valery, Patricia C, Bernardes, Christina M, Stuart, Katherine A, Hartel, Gunter F, McPhail, Steven M, Skoien, Richard, Rahman, Tony, Clark, Paul J, Horsfall, Leigh U, Hayward, Kelly L, Gupta, Rohit, and Powell, Elizabeth E

Subjects
perceived needs, Patient Preference and Adherence, chronic liver disease, psychometric properties, Original Research, instrument validation
Abstract

Patricia C Valery,1,2 Christina M Bernardes,1 Katherine A Stuart,3 Gunter F Hartel,1 Steven M McPhail,4 Richard Skoien,5 Tony Rahman,6 Paul J Clark,7 Leigh U Horsfall,2,3 Kelly L Hayward,2 Rohit Gupta,8 Elizabeth E Powell2,3 1QIMR Berghofer Medical Research Institute, Herston, QLD, Australia; 2Centre for Liver Disease Research, Translational Research Institute, Faculty of Medicine, The University of Queensland, Brisbane, QLD, Australia; 3Department of Gastroenterology and Hepatology, Princess Alexandra Hospital, Brisbane, QLD, Australia; 4Centre for Functioning and Health Research, Queensland Health and the School of Public Health and Institute of Health and Biomedical Innovation, Queensland University of Technology, Brisbane, QLD, Australia; 5Department of Gastroenterology, Royal Brisbane and Women’s Hospital, Brisbane, QLD, Australia; 6Gastroenterology & Hepatology Department, The Prince Charles Hospital, Chermside, QLD, Australia; 7Department of Gastroenterology and Hepatology, Mater Hospitals, Brisbane, QLD, Australia; 8Department of Gastroenterology and Hepatology, Sunshine Coast University Hospital, Birtinya, QLD, AustraliaCorrespondence: Patricia C ValeryQIMR Berghofer Medical Research Institute, 300 Herston Road, Herston, QLD 4006, AustraliaTel +61 7 33620376Email Patricia.Valery@qimrberghofer.edu.auBackground: We report the development and psychometric testing of a Supportive Needs Assessment tool for Cirrhosis (SNAC).Methods: The 50-item SNAC was administered to patients (n=465) diagnosed with cirrhosis recruited from five metropolitan hospitals in Queensland, Australia. Items were assessed for ceiling and floor effects, and exploratory factor analysis was used to assess the factor structure. Identified factors were assessed for internal consistency and convergent validity to validated psychosocial tools.Results: Exploratory factor analysis identified 4 factors (39 items), which together accounted for 49.2% of the total variance. The 39-item SNAC met the requirements of a needs assessment tool and identified a range of needs important to patients with cirrhosis that were grouped in four subscales: “Psychosocial issues”, “Practical and physical needs”, “Information needs”, and “Lifestyle changes”. Cronbach’s alpha values for the four subscales ranged from 0.64 to 0.92. Convergent validity was supported by a strong correlation between the total SNAC score and that of the Chronic Liver Disease Questionnaire (CLDQ; Spearman rho − 0.68; p< 0.001), and moderate correlations with the Distress Thermometer (Spearman rho 0.53; p< 0.001) and seven subscales of a generic health-related quality of life instrument (Short Form 36; Spearman rho ranged from − 0.48 to − 0.57; p< 0.001). The SNAC discriminated patient groups with respect to sex (p=0.013), age group (p< 0.001), and hospital admission status (admitted vs not; p< 0.001).Conclusion: These data provide initial evidence for the validity and reliability of the SNAC, an instrument designed to measure type and amount of perceived unmet practical and psychological needs of people diagnosed with cirrhosis.Keywords: chronic liver disease, perceived needs, instrument validation, psychometric properties

Published
2020

20. Prothrombinex®-VF in chronic liver disease: Friend or foe?

Author

LATONA, Akmez, HILL, Kate, CONNELLY, Aurelia, STUART, Katherine, and WOOD, Peter

Subjects
DISSEMINATED intravascular coagulation, RESEARCH, PARTIAL thromboplastin time, PROTHROMBIN time, VEINS, RETROSPECTIVE studies, CIRRHOSIS of the liver, FIBRINOLYSIS, LIVER diseases, THROMBOEMBOLISM, FIBRINOGEN, BLOOD coagulation factors, INTERNATIONAL normalized ratio, LIVER failure, HEMORRHAGE
Abstract

Objective: Management of coagulopathy in chronic liver disease (CLD) poses a challenge for critical care physicians. Prothrombinex®-VF is a low-volume product with rapid onset of action. Evidence for its efficacy and safety in CLD is limited and cases of acute intravascular coagulation and fibrinolysis (AICF) and/or disseminated intravascular coagulation (DIC) have been reported. Our objective was to evaluate the role of Prothrombinex®-VF in reversal of coagulopathy and the incidence AICF/DIC, thromboembolic events and mortality. Methods: This was a retrospective, multi-centre study of Prothrombinex®-VF use in CLD across 11 hospitals over a 2-year period, excluding those on therapeutic anticoagulation. Patients were subclassified into acute on chronic liver failure (ACLF), acute decompensation (ADC) and compensated cirrhosis. Reversal of coagulopathy was defined as international normalised ratio (INR) <1.5 x upper limit normal (ULN), prothrombin time <1.5 x ULN, activated partial thromboplastin time <1.5 x ULN and fibrinogen >1 g/L. Markers of AICF/DIC were recorded. Results: Thirty CLD patients were included, and the median model for end-stage liver disease score was 23.5. Acute bleeding was the most common indication for Prothrombinex®-VF (60%). All had baseline coagulopathy and the majority did not achieve reversal. Key indicators of AICF/DIC were mainly observed in those with ACLF; bleeding from mucosa or lines (53%), worsening hypofibrinogenaemia (60%), worsening thrombocytopaenia (60%). The ADC and compensated cirrhosis groups were relatively unaffected. Incidence of venous thromboembolism was 6%. Overall mortality was 43% and 70% in ACLF. Conclusion: Prothrombinex®-VF did not lead to meaningful reversal of coagulopathy and should be used with caution in CLD. Patients with ACLF were more likely to develop AICF/DIC following Prothrombinex®-VF, although the association is uncertain. Further studies are needed to evaluate the safety and efficacy of Prothrombinex®-VF use in CLD. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

22. Methods of Manufacturing Bioactive Gels from Extracellular Matrix Material

Author

Kentner, Kimberly A, Stuart, Katherine A, and Janis, Abram D

Subjects
Life Sciences (General)
Abstract

The present invention is directed to methods of manufacturing bioactive gels from ECM material, i.e., gels which retain bioactivity, and can serve as scaffolds for preclinical and clinical tissue engineering and regenerative medicine approaches to tissue reconstruction. The manufacturing methods take advantage of a new recognition that bioactive gels from ECM material can be created by digesting particularized ECM material in an alkaline environment and neutralizing to provide bioactive gels.

Published
2016

23. Daclatasvir in Combination With Asunaprevir and Beclabuvir for Hepatitis C Virus Genotype 1 Infection With Compensated Cirrhosis

Author

Muir, Andrew J., Poordad, Fred, Lalezari, Jacob, Everson, Gregory, Dore, Gregory J., Herring, Robert, Sheikh, Aasim, Kwo, Paul, Hézode, Christophe, Pockros, Paul J., Tran, Albert, Yozviak, Joseph, Reau, Nancy, Ramji, Alnoor, Stuart, Katherine, Thompson, Alexander J., Vierling, John, Freilich, Bradley, Cooper, James, Ghesquiere, Wayne, Yang, Rong, McPhee, Fiona, Hughes, Eric A., Swenson, E. Scott, and Yin, Philip D.

Published
2015
Full Text
View/download PDF

25. Monitoring quality of care in hepatocellular carcinoma: A modified Delphi consensus.

Author

Maharaj, Ashika D., Lubel, John, Lam, Eileen, Clark, Paul J., Duncan, Oliver, George, Jacob, Jeffrey, Gary P., Lipton, Lara, Liu, Howard, McCaughan, Geoffrey, Neo, Eu‐Ling, Philip, Jennifer, Strasser, Simone I., Stuart, Katherine, Thompson, Alexander, Tibballs, Jonathan, Tu, Thomas, Wallace, Michael C., Wigg, Alan, and Wood, Marnie

Subjects
HEPATOCELLULAR carcinoma, ABLATION techniques, DIAGNOSTIC imaging, TUMOR classification, PATHOLOGICAL laboratories
Abstract

Although there are several established international guidelines on the management of hepatocellular carcinoma (HCC), there is limited information detailing specific indicators of good quality care. The aim of this study was to develop a core set of quality indicators (QIs) to underpin the management of HCC. We undertook a modified, two‐round, Delphi consensus study comprising a working group and experts involved in the management of HCC as well as consumer representatives. QIs were derived from an extensive review of the literature. The role of the participants was to identify the most important and measurable QIs for inclusion in an HCC clinical quality registry. From an initial 94 QIs, 40 were proposed to the participants. Of these, 23 QIs ultimately met the inclusion criteria and were included in the final set. This included (a) nine related to the initial diagnosis and staging, including timing to diagnosis, required baseline clinical and laboratory assessments, prior surveillance for HCC, diagnostic imaging and pathology, tumor staging, and multidisciplinary care; (b) thirteen related to treatment and management, including role of antiviral therapy, timing to treatment, localized ablation and locoregional therapy, surgery, transplantation, systemic therapy, method of response assessment, and supportive care; and (c) one outcome assessment related to surgical mortality. Conclusion: We identified a core set of nationally agreed measurable QIs for the diagnosis, staging, and management of HCC. The adherence to these best practice QIs may lead to system‐level improvement in quality of care and, ultimately, improvement in patient outcomes, including survival. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

26. Methods of Manufacturing Bioactive Gels from Extracellular Matrix Material

Author

Kentner, Kimberly A, Stuart, Katherine A, and Janis, Abram D

Subjects
Life Sciences (General)
Abstract

The present invention is directed to methods of manufacturing bioactive gels from ECM material, i.e., gels which retain bioactivity, and can serve as scaffolds for preclinical and clinical tissue engineering and regenerative medicine approaches to tissue reconstruction. The manufacturing methods take advantage of a new recognition that bioactive gels from ECM material can be created by digesting particularized ECM material in an alkaline environment and neutralizing to provide bioactive gels.

Published
2015

29. Methods of Manufacturing Bioactive Gels from Extracellular Matrix Material

Author

Kentner, Kimberly A, Stuart, Katherine A, and Janis, Abram D

Subjects
Life Sciences (General)
Abstract

The present invention is directed to methods of manufacturing bioactive gels from ECM material, i.e., gels which retain bioactivity, and can serve as scaffolds for preclinical and clinical tissue engineering and regenerative medicine approaches to tissue reconstruction. The manufacturing methods take advantage of a new recognition that bioactive gels from ECM material can be created by digesting particularized ECM material in an alkaline environment and neutralizing to provide bioactive gels.

Published
2014

33. Predicting Liver‐Related Outcomes in People With Nonalcoholic Fatty Liver Disease: The Prognostic Value of Noninvasive Fibrosis Tests.

Author

Johnson, Amy L., Hayward, Kelly L., Patel, Preya, Horsfall, Leigh U., Cheah, Alvin Ee Zhiun, Irvine, Katharine M., Russell, Anthony W., Stuart, Katherine A., Williams, Sue, Hartel, Gunter, Valery, Patricia C., and Powell, Elizabeth E.

Subjects
NON-alcoholic fatty liver disease, PROGNOSIS, HEPATIC fibrosis, FIBROSIS, ELECTRONIC health records
Abstract

It remains unclear whether screening for advanced fibrosis in the community can identify the subgroup of people with nonalcoholic fatty liver disease (NAFLD) at higher risk for development of liver‐related complications. We aimed to determine the prognostic value of baseline noninvasive fibrosis tests for predicting liver‐related outcomes and mortality in patients with NAFLD from type 2 diabetes (T2D) clinics or primary care. Patients (n = 243) who were screened for NAFLD with advanced fibrosis by using NAFLD fibrosis score (NFS), fibrosis 4 score (FIB‐4), enhanced liver fibrosis (ELF) test, and liver stiffness measurements (LSMs) were followed up for clinical outcomes by review of electronic medical records. During a median follow‐up of 50 months, decompensated liver disease or primary liver cancer occurred in 6 of 35 (17.1%) patients with baseline LSM > 13 kPa, 1 of 17 (5.9%) patients with LSM 9.5‐13 kPa, and in no patients with LSM < 9.5 kPa. No patient with low‐risk NFS developed liver decompensation or liver‐related mortality. Following repeat NFSs at the end of follow‐up, all patients with a liver‐related complication were in the high‐risk NFS category. Patients who developed liver‐related complications were also more likely to have baseline high‐risk FIB‐4 scores or ELF test ≥9.8 compared to patients who did not develop liver outcomes. Conclusion: Liver fibrosis risk stratification in non‐hepatology settings can identify the subset of patients at risk of liver‐related complications. Although the rate of development of a decompensation event or hepatocellular carcinoma was low (2.1% per year) in our patients with compensated cirrhosis (LSM > 13 kPa), these events are projected to lead to a substantial increase in NAFLD‐related disease burden over the next decade due to the high prevalence of NAFLD in people with obesity and T2D. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

39. Turning the Tide on Hepatitis C Virus–Related Liver Transplantation: The Return on Investment in Hepatitis C Virus Treatment in Australia and New Zealand.

Author

Howell, Jess, Majumdar, Avik, Fink, Michael A., Byrne, Mandy, McCaughan, Geoff, Strasser, Simone I., Crawford, Michael, Hodgkinson, Peter, Stuart, Katherine A., Tallis, Caroline, Chen, John, Wigg, Alan, Jones, Robert, Jaques, Bryon, Jeffrey, Gary, Adams, Leon, Wallace, Michael C., Munn, Stephen, Gane, Ed, and Thompson, Alex J.

Published
2022
Full Text
View/download PDF

40. Management, outcomes and survival of an Australian IgG4‐SC cohort: The MOSAIC study.

Author

Kemp, William, Majeed, Ammar, Mitchell, Joanne, Majumdar, Avik, Tse, Edmund, Skoien, Richard, Croagh, Daniel, Dev, Anouk, Gao, Hugh, Weltman, Martin, Craig, Philip, Stuart, Katherine, Cheng, Wendy, Edmunds, Simon, Lee, Eric, Sood, Siddharth, Metz, Andrew, Thompson, Alexander, Sinclair, Marie, and Beswick, Lauren

Subjects
CHOLANGITIS, SURVIVAL rate, BILIARY tract, BILE ducts, COHORT analysis, CONDITIONED response
Abstract

Background and Aims: IgG4 sclerosing cholangitis (IgG4‐SC) is the biliary component of the multisystem IgG4‐related disease. We aimed to investigate the clinical features, demographics, treatment response and outcomes of IgG4‐SC in a large Australian cohort. Methods: We conducted nationwide retrospective cohort via the Australian Liver Association Clinical Trials Network (ALA‐CRN). 39 sites were invited to participate. IgG4‐SC was defined by the clinical diagnostic criteria established by the Japanese Biliary Association in 2012. Data were collected on patient demographic, clinical and laboratory information, presenting features, response to therapy and clinical outcomes. Results: 67 patients meet inclusion criteria from 22 sites. 76% were male with mean age of 63.3 ± 14.5 years and a median IgG4 level of 3.6 g/L [0.09‐67.1]. The most frequent presenting symptom was jaundice (62%) and abdominal pain (42%) and Type 1 biliary stricturing (52%) at the distal common bile duct was the most frequent biliary tract finding. Prednisolone was used as a primary treatment in 61 (91%) and partial or complete response occurred in 95% of subjects. Relapse was common (42%) in those who ceased medical therapy. After a median follow up of 3.9 years there was one hepatocellular carcinoma and no cholangiocarcinomas. Conclusions: Our study confirms the preponderance of IgG4‐SC in males and highlights the steroid response nature of this condition although relapse is common after steroid cessation. Progression to malignancy was uncommon. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

42. Disparities in Unmet Needs in Indigenous and Non-Indigenous Australians with Cirrhosis: An Exploratory Study.

Author

Bernardes, Christina M, Clark, Paul J, Brown, Cath, Stuart, Katherine, Pratt, Gregory, Toombs, Maree, Hartel, Gunter, Powell, Elizabeth E, and Valery, Patricia C

Subjects
INDIGENOUS Australians, CIRRHOSIS of the liver, POISSON regression
Abstract

Purpose: Understanding and responding to the supportive care needs of people with cirrhosis is essential to quality care. Indigenous Australians, Aboriginal and Torres Strait Islander people, are overrepresented amongst patients with cirrhosis. This study documented the nature and extent of supportive care needs of Indigenous Australians with cirrhosis, in comparison with non-Indigenous Australians. Patients and Methods: The supportive care needs of adult patients diagnosed with cirrhosis attending public hospitals in Queensland were assessed through the Supportive Needs Assessment tool for Cirrhosis (SNAC). Patients indicated how much additional help they needed on four subscales: 1. psychosocial issues; 2. practical and physical needs; 3. information needs; and 4. lifestyle changes. We examined the rate of moderate-to-high unmet needs based on Indigenous status (Poisson regression; incidence rate ratio (IRR)). Results: Indigenous (n=20) and non-Indigenous (n=438) patients included in the study had similar sociodemographic and clinical characteristics except for a lower educational level among Indigenous patients (p< 0.01). Most Indigenous patients (85.0%) reported having moderate-to-high unmet needs with at least one item in the SNAC tool. Following adjustment for key sociodemographic and clinical factors, Indigenous patients had a greater rate of moderate-to-high unmet needs overall (IRR=1.5, 95% CI 1.31– 1.72; p< 0.001), and specifically for psychosocial issues (IRR=1.7, 95% CI 1.39– 2.15; p< 0.001), and practical and physical needs subscales (IRR=1.5, 95% CI 1.22– 1.83; p< 0.001), compared to non-Indigenous patients. Conclusion: Indigenous Australians with cirrhosis more frequently had moderate-to-high unmet supportive care needs than non-Indigenous patients. Specific targeting of culturally appropriate supportive care for psychosocial, practical and physical needs may optimize cirrhosis care and improve the quality of life for Indigenous Australians with cirrhosis. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

43. Efficacy and Safety of Sofosbuvir/Velpatasvir/Voxilaprevir for Hepatitis C Virus (HCV) NS5A-Inhibitor Experienced Patients With Difficult to Cure Characteristics.

Author

Papaluca, Timothy, Roberts, Stuart K, Strasser, Simone I, Stuart, Katherine A, Farrell, Geoffrey, MacQuillan, Gerry, Dore, Gregory J, Wade, Amanda J, George, Jacob, Hazeldine, Simon, O'Beirne, James, Wigg, Alan, Fisher, Leslie, McGarity, Bruce, Sawhney, Rohit, Sinclair, Marie, Thomas, James, Valiozis, Ivan, Weltman, Martin, and Wilson, Mark

Subjects
DRUG efficacy, PROTEINS, CLINICAL trials, ANTIVIRAL agents, HEPATITIS C, CIRRHOSIS of the liver, TREATMENT effectiveness, LIVER diseases, SYMPTOMS, DESCRIPTIVE statistics, SALVAGE therapy, PORTAL hypertension, LIVER transplantation, DRUG side effects, INTENTION, DATA analysis software, PATIENT safety, CHEMICAL inhibitors, EVALUATION
Abstract

Background In clinical trials, hepatitis C virus (HCV) salvage treatment with sofosbuvir/velpatasvir/voxilaprevir (SOF/VEL/VOX) achieved an SVR12 rate of >95% in NS5A-experienced participants. Lower SVR12 rates have been reported in real-world studies, particularly for genotype (GT)3 infection and cirrhosis. We determined the efficacy and safety of SOF/VEL/VOX in a large real-world cohort. Methods We assessed the efficacy of salvage SOF/VEL/VOX for HCV infection in NS5A-inhibitor experienced participants with cirrhosis and portal hypertension, prior liver transplantation (LT) or severe extra-hepatic manifestations. SOF/VEL/VOX was available via an early access program. The primary outcome was SVR12. Secondary outcome was frequency of adverse events (AE). Findings Ninety-seven participants were included. Median age was 58, 82% were male, 78% had cirrhosis, most with portal hypertension (61%, n = 46/76), and 18% had prior-LT. Of the cirrhotic participants, 96% were Child-Turcotte-Pugh class A, and 4% were class B. Of the 72% with GT3, 76% were also cirrhotic. By intention-to-treat analysis, SVR12 rate was 85% (n = 82/97). Per protocol, the SVR12 rate was 90%, including 91% in GT1 (GT1a n = 18/18, GT1b n = 2/4), 89% in GT3 (n = 59/66) and 100% in GT6 (n = 3/3). SVR12 in participants with GT3 and cirrhosis was 90%. No predictors of non-SVR12 were identified. There were 4 serious AEs including 1 death and 3 hepatic decompensation events. NS5A resistance-associated substitutions detected at baseline did not affect SVR12. Conclusions This real-world study confirms high efficacy of SOF/VEL/VOX for the treatment of difficult-to-cure NS5A-inhibitor experienced patients, including those with GT3 and cirrhosis. Treatment was well tolerated in most; however, serious AEs can occur in those with advanced liver disease. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

45. Stereotactic body radiotherapy in the management of hepatocellular carcinoma: An Australian multi-institutional patterns of practice review.

Author

Liu, Howard Yu‐hao, Lee, Yoo‐young Dominique, Sridharan, Swetha, Choong, Ee Siang, Le, Hien, Wang, Wei, Khor, Richard, Chu, Julie, Oar, Andrew, Mott, Rebekah, Smart, Joanne, Jenkins, Trish, Anderson, Nigel, Cross, Shamira, Loo, Kee Fong, Wigg, Alan, Stuart, Katherine, Pryor, David, Liu, Howard Yu-Hao, and Lee, Yoo-Young Dominique

Subjects
STEREOTACTIC radiotherapy, HEPATOCELLULAR carcinoma, LIVER cancer, CIRRHOSIS of the liver, AUSTRALIANS, DRUG labeling
Abstract

Introduction: Stereotactic body radiotherapy (SBRT) is an emerging, therapeutic option in the management of hepatocellular carcinoma (HCC). A multicentre Liver Ablative Stereotactic Radiation (LASR) database was established to provide a collaborative platform for Australian institutions to define the practice of liver SBRT for HCC. This study explores the patterns of SBRT practice amongst Australian institutions.Methods: This was a multi-institutional retrospective study of patients treated with SBRT for HCC at 10 institutions between January 2013 and December 2019. Patients' demographics, disease characteristics and SBRT details were evaluated.Results: Three hundred and seventeen patients were evaluated with a median age of 67 years (range, 32-90). Liver cirrhosis was present in 88.6%, baseline Child-Pugh score was A5/6 in 85.1% and B7/8 in 13.2%. Median size of HCC treated was 30 mm (range, 10-280). 63.1% had early-stage disease (Barcelona clinic liver cancer (BCLC) stage 0/A) and 36% had intermediate/advanced-stage disease (BCLC B/C). In 2013/2014, six courses of SBRT were delivered, increasing to 108 in 2019. SBRT was prescribed in five fractions for 71.3% of the cohort. The most common dose fractionation schedule was 40 Gy in five fractions (24.3%). Median biologically effective dose (BED10 ) delivered was 85.5 Gy for early-stage and 60 Gy for intermediate/advanced disease, respectively. The most common prescription range was 100-120 Gy BED10 (32.8%).Conclusion: SBRT utilisation for HCC is increasing in Australia. There was wide variation in size of tumours and disease stages treated, and prescription patterns. Uniform reporting of clinical and dosimetric details are important in refining the role of liver SBRT. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

46. In Reply to Drs Lipman and Hackett

Author

Kanaan, Nicholas C., Peterson, Alicia L., Pun, Matiram, Thapa, Ghan B., Tiwari, Aditya, Basyal, Bikash, Holck, Peter S., Starling, Jennifer, Freeman, Thomas F., Gehner, Jessica R., Keyes, Linda, Levin, Dana R., O’Leary, Catherine J., Stuart, Katherine E., Velgersdyk, Jared L., Zafren, Ken, and Basnyat, Buddha

Published
2017
Full Text
View/download PDF

48. The Patient's Perspective in Cirrhosis: Unmet Supportive Care Needs Differ by Disease Severity, Etiology, and Age.

Author

Valery, Patricia C., Bernardes, Christina M., Mckillen, Benjamin, Amarasena, Samath, Stuart, Katherine A., Hartel, Gunter, Clark, Paul J., Skoien, Richard, Rahman, Tony, Horsfall, Leigh, Hayward, Kelly, Gupta, Rohit, Lee, Andrew, Pillay, Leshni, and Powell, Elizabeth E.

Subjects
CIRRHOSIS of the liver, LIVER diseases, DYSLIPIDEMIA
Abstract

Patients with cirrhosis have significant physical, psychological, and practical needs. We documented patients' perceived need for support with these issues and the differences with increasing liver disease severity, etiology, and age. Using the supportive needs assessment tool for cirrhosis (SNAC), we examined the rate of moderate‐to‐high unmet needs (Poisson regression; incidence rate ratio [IRR]) and the correlation between needs and sociodemographic/clinical characteristics (multivariable linear regression) in 458 Australians adults with cirrhosis. Primary liver disease etiology was alcohol in 37.6% of patients, chronic viral hepatitis C in 25.5%, and nonalcoholic fatty liver disease (NAFLD)/nonalcoholic steatohepatitis (NASH) in 23.8%. A total of 64.6% of patients had Child‐Pugh class A cirrhosis. Most patients (81.2%) had at least one moderate‐to‐high unmet need item; more than 25% reported a moderate‐to‐high need for help with "lack of energy," "sleep poorly," "feel unwell," "worry about ... illness getting worse (liver cancer)," "have anxiety/stress," and "difficulty with daily tasks." Adjusting for key sociodemographic/clinical factors, patients with Child‐Pugh C had a greater rate of "practical and physical needs" (vs. Child‐Pugh A; IRR = 2.94, 95% confidence interval [CI] 2.57‐3.37), patients with NAFLD/NASH had a greater rate of needs with "lifestyle changes" (vs. alcohol; IRR = 1.81, 95% CI 1.18‐2.77) and "practical and physical needs" (IRR = 1.43, 95% CI 1.23‐1.65), and patients aged ≥65 years had fewer needs overall (vs. 18‐64 years; IRR = 0.70, 95% CI 0.64‐0.76). Higher overall SNAC scores were associated with Child‐Pugh B and C (both P < 0.001), NAFLD/NASH (P = 0.028), patients with "no partner, do not live alone" (P = 0.004), unemployment (P = 0.039), ascites (P = 0.022), and dyslipidemia (P = 0.024) compared with their counterparts. Conclusion: Very high levels of needs were reported by patients with cirrhosis. This information is important to tailor patient‐centered care and facilitate timely interventions or referral to support services. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

49. Changing prevalence of aetiological factors and comorbidities among Australians hospitalised for cirrhosis.

Author

Valery, Patricia C., McPhail, Steven, Stuart, Katherine A., Hartel, Gunter, Clark, Paul J., O'Beirne, James, Skoien, Richard, Rahman, Tony, Moser, Chris, and Powell, Elizabeth E.

Subjects
HEPATITIS B, ALCOHOLIC liver diseases, FATTY liver, CIRRHOSIS of the liver, RETROSPECTIVE studies, HEPATITIS C, TYPE 2 diabetes, HOSPITAL care, DESCRIPTIVE statistics, DISEASE prevalence, COMORBIDITY, LONGITUDINAL method
Abstract

Background: The rate of hospital admissions for cirrhosis increased 1.3‐fold during 2008–2016 in Queensland. Alcohol misuse was a contributing factor for cirrhosis in 55% of admissions and 40% of patients had at least one comorbidity. Aims: To examine the temporal change in aetiology of liver disease and presence of comorbidity in patients admitted with cirrhosis. Methods: Population‐based retrospective cohort study of all people treated in hospital for cirrhosis (10 254 patients) in Queensland during 2008–2016. Data were sourced from Queensland Hospital Admitted Patient Data Collection. Results: The commonest aetiology was alcohol (49.5%), followed by cryptogenic (unspecified cirrhosis; 28.5%), hepatitis C virus (19.3%), non‐alcoholic fatty liver disease (NAFLD)/non‐alcoholic steatohepatitis (NASH) (4.8%) and hepatitis B virus (HBV) (4.3%). The prevalence of alcohol‐related (P = 0.41) and hepatitis C virus (P = 0.08) remained stable between 2008–2010 and 2014–2016, that of NAFLD/NASH, cryptogenic and HBV‐cirrhosis increased by 67% (P < 0.00001), 27% (P < 0.00001) and 20% (P = 0.00019), respectively; 41.1% of patients had at least one comorbidity. The prevalence of type 2 diabetes nearly doubled (from 13.7% to 25.4%; P < 0.00001) between 2008–2010 and 2014–2016. Conclusions: Alcohol misuse was the most important aetiology. The importance of NAFLD/NASH, cryptogenic and HBV‐cirrhosis and the burden of comorbidity increased during 2008–2016. Ongoing alcohol misuse and the increasing prevalence of NAFLD/NASH, cryptogenic cirrhosis and comorbid type 2 diabetes among admissions for cirrhosis has implications for public health interventions to reduce the burden of unhealthy lifestyle and metabolic disorders. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

50. Stereotactic radiotherapy for hepatocellular carcinoma: Expanding the multidisciplinary armamentarium.

Author

Shanker, Mihir D, Liu, Howard Y, Lee, Yoo Young, Stuart, Katherine A, Powell, Elizabeth E, Wigg, Alan, and Pryor, David I

Subjects
STEREOTACTIC radiotherapy, PROGNOSIS, PATIENT selection, LIVER diseases
Abstract

Hepatocellular carcinoma (HCC) is the fifth most common malignancy worldwide and the third most common cause of cancer‐related death. Long‐term prognosis remains poor with treatment options frequently limited by advanced tumor stage, tumor location, or underlying liver dysfunction. Stereotactic ablative body radiotherapy (SABR) utilizes technological advances to deliver highly precise, tumoricidal doses of radiation. There is an emerging body of literature on SABR in HCC demonstrating high rates of local control in the order of 80–90% at 3 years. SABR is associated with a low risk of radiation‐induced liver disease or decompensation in appropriately selected HCC patients with compensated liver function and is now being incorporated into guidelines as an additional treatment option. This review outlines the emerging role of SABR in the multidisciplinary management of HCC and summarizes the current evidence for its use as an alternative ablative option for early‐stage disease, as a bridge to transplant, and as palliation for advanced‐stage disease. We outline specific considerations regarding patient selection, toxicities, and response assessment. Finally, we compare current international guidelines and recommendations for the use of SABR and summarize ongoing studies. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results